Make a gift by December 2nd, 2025 to double your impact.
By Anna Greene, PhD, NETRF Director of Research We’re excited to share insights from a new ENETS (European Neuroendocrine Tumor Society) position statement, published in
By Anne-Marie Green, NETRF Director of Digital Communications NETRF brought the NET Impact Thrivership & Research Education Program to Alabama for the first time on
By Anne-Marie Green, Director of Digital Communications As a 19-year veteran educator, Dr. Barbara Dunham’s learning instincts were set in motion when she was diagnosed
Congress recently passed new tax legislation that will change how charitable contributions are treated starting in 2026. While the bill is complex, we want to
The world’s first clinical trial for CAR T-cell therapy in neuroendocrine tumors has advanced to a higher dose level, an indication of progress. Advancing to
We did it! Thanks to our incredible NETRF community and the generous match from our board member Steve Kaufer, we raised over $115,000 for neuroendocrine
At NETRF, our dedication to advancing research is paramount because it holds the key to improving treatments and ultimately finding cures for neuroendocrine cancer. Research
The results of a phase 2 clinical trial, the Natalie Trial, suggest that the drug cabozantinib may hold promise as a therapeutic option for some
The U.S. Food and Drug Administration approved Lutathera® as the first therapy specifically for patients 12 to 17 years of age who have somatostatin receptor-positive
Carrie Camino joined the NETRF Board of Directors in April of 2024. Carrie is a retired business consultant and partner with West Monroe Partners, where